Expanding Value Assessment Beyond Drugs
Jennifer Bright writes in Morning Consult that while we’ve made progress assessing the value of biopharmaceuticals, more focus is needed to develop bout transparent, patient-centered value assessment methods in healthcare technologies beyond drugs. Read the full article here.
IVI Unveils Updates to Rheumatoid Arthritis Model
The Center for Biosimilars writes about IVI’s recent updates to their IVI-RA value model to include biosimilars, triple therapy, Janus kinase (JAK) inhibitors, sarilumab, as well as updated treatment effect estimates based on additional randomized control trial (RCT) evidence, and updated cost estimates. Read the full article here.
What’s in Store for 2020?
Jennifer Bright discusses the following three trends that began in 2019 and will pick up steam this year: Increased demand for value information for drugs; Increased number of voices asking whether value assessment is done the right way; and Momentum to improve value assessment models. Read the full article here. Please note that a Scrip […]
The Ascendency of Value Assessment
Value assessment is a hot topic in healthcare. But how can it be improved so it’s more relevant to answering the most important questions to patients, payers and providers? In this commentary, Jennifer Bright explains why we need data partners to catalyze improvement in value assessment. Read the article here.
IVI Showcases OSVP at HealthEconomics.com’s “Big Ideas Accelerating Change” Challenge
As one of the nine finalists in HealthEconomics.com‘s inaugural challenge competition to accelerate change in health economics and outcomes research, IVI’s Mark Linthicum offered a compelling case for how IVI’s Open-Source Value Platform (OSVP) is catalyzing innovation to shake up value assessment. Mark’s presentation, “Using Open-Source Models to Improve Value Assessment in the U.S.”, outlined […]
IVI Submits Comments on ICER Draft Evidence Report on JAK Inhibitors for RA
IVI offered comments on ICER’s recently released Draft Evidence Report examining the cost-effectiveness of Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis. In addition to commenting on the needs for transparency and the impacts of modeling assumptions on results, IVI’s comments raise a broader question about the relevance of the analysis to decision making. IVI writes […]
Jennifer Bright Explains How IVI Economic Models Improve Process of Value Assessment
At the National Health Council’s event, Back to School: Patient Community Training on Value Assessment, IVI executive director Jennifer Bright explains the non-profit organization’s mission to make value assessment more relevant to real decision making, how and why patient perspectives must be built into the front end of economic modeling, and how patients and patient […]
Top Three Questions Employers Need to Ask Benefits Consultants
Jennifer Bright writes in Benefits Pro that employers who rely on health plans and vendors to advise them on coverage for drugs or other treatments need to ask several key questions to ensure they are getting the most value out of their consultants’ recommendations. Read the full article here.
IVI Comment Letter on ICER’s Proposed Methods for Curative Therapies
IVI submitted comments to ICER regarding proposed methodological changes for assessments of the value of single or short-term transformative (SST) therapies. IVI emphasized the need for ICER to address the potential use of its findings by decision makers, specifically when short-term budget estimates may discourage investment in therapies with high long-term value, including careful consideration […]
Watch Devin Incerti Discuss the Need for Adaptable Value Assessment Approaches
Devin Incerti sat down with the AJMC media team at the 2019 ISPOR conference to discuss how value is context-specific and therefore value assessment should be too. Watch the interview here.